Johnson & Johnson's TAR-200 Plus Cetrelimab Nearly Doubles Cancer Response Rate in Bladder Cancer Phase 2 Trial
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's Phase 2 trial of TAR-200 plus cetrelimab shows promising results in bladder cancer treatment, nearly doubling the response rate compared to cetrelimab alone.
September 16, 2024 | 6:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Phase 2 trial of TAR-200 plus cetrelimab in bladder cancer shows promising results, nearly doubling the response rate compared to cetrelimab alone. This could enhance JNJ's oncology portfolio and impact its stock positively.
The positive interim results from the Phase 2 trial of TAR-200 plus cetrelimab suggest a significant advancement in JNJ's oncology treatments, potentially boosting investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100